rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

JIN MEDICAL INTERNATIONAL LTD. - Class A

ZJYL · Nasdaq

Health CareMedical DevicesSetting up

ZJYL stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 5.6% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Setting up
Weeks in an uptrend
out for 52
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
4 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders4+2 on the quarter
New · exited2 · 0
Reported value$7,413

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
OSAIC HOLDINGS, INC.unchanged · filed 14 Aug 20263,100$5,64200.0%
UBS Group AGreduced · filed 13 Aug 2026971$1,767-252−20.6%
MERCER GLOBAL ADVISORS INCnew · filed 11 Aug 20261$2+1
Caitong International Asset Management Co., Ltdnew · filed 5 Aug 20261$2+1
31 Mar 2024 – 30 Jun 2026
31016Mar 24Sep 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Nobody on record has traded it.

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 30 Sep 202529.2%
Operating profit marginFY 2025 · to 30 Sep 20252.9%
Free cash flow marginFY 2025 · to 30 Sep 2025-18.0%
Return on capital employedFY 2025 · to 30 Sep 20252.1%
Cash conversionFY 2025 · to 30 Sep 2025244%
Debt to equityFY 2025 · to 30 Sep 20250.64×
Research spendFY 2025 · to 30 Sep 20257.5%
Revenue growthFY 2025 · to 30 Sep 2025-12.0%
Earnings per share growthFY 2025 · to 30 Sep 2025-50.0%
Share count trendFY 2025 · to 30 Sep 20250.0%
Cash and equivalentsFY 2025 · to 30 Sep 2025$7.5M
Free cash flowFY 2025 · to 30 Sep 2025−$3.7M

Analyst forecasts

No analyst forecasts yet.